Cristina Saura

Also affiliated with Universitat Autònoma de Barcelona, Breast Cancer Research Foundation, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Solti, Vall d'Hebron Institute of Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer”.

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2212856

N/A

4.5DataRank · unranked

216 citations

Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni +34 more

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Annals of Oncology(2023)10.1016/j.annonc.2023.08.003

N/A

1.4DataRank · unranked

61 citations

L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni +37 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

npj Breast Cancer(2022)10.1038/s41523-022-00430-0

N/A

0.417DataRank · unranked

8 citations

Zhuo Li, Daniel Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner +20 more

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

The Breast(2025)10.1016/j.breast.2025.104547

N/A

0.165DataRank · unranked

2 citations

Samuel M. Niman, Ann H. Partridge, Daniela Diego, Roswitha Kammler, Monica Ruggeri +31 more

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Research(2022)10.1158/0008-5472.can-21-2409

N/A

0DataRank · unranked

98 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2657

N/A

0DataRank · unranked

39 citations

Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk +16 more

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

The Lancet Oncology(2020)10.1016/s1470-2045(20)30450-2

N/A

0DataRank · unranked

75 citations

Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci +34 more

Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

ESMO Open(2023)10.1016/j.esmoop.2023.102031

N/A

0DataRank · unranked

31 citations

Eva Blondeaux, Marco Bruzzone, Maria Maddalena Latocca, Elene Mariamidze, S. Begijanashvili +16 more

Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

(2023)10.1158/0008-5472.c.6513876.v1

N/A

0DataRank · unranked

0 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy

Journal of Clinical Oncology(2024)10.1200/jco.23.02292

N/A

0DataRank · unranked

27 citations

Samuel M. Niman, Ann H. Partridge, Isabelle Demeestere, Monica Ruggeri, Marco Colleoni +31 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

UNC Libraries(2025)10.17615/kfcn-nf74

N/A

0DataRank · unranked

0 citations

Afshin Mashadi-Hossein, Kathleen Tenner, Lisa A. Carey, Zhuo Li, Heather Ann Brauer +20 more